PIK3CA and breast carcinoma: Despite the attention of researchers on PIK3CA, alpelisib (BYL-719) is the only p110α inhibitor that is FDA-indicated for use in breast cancer and only in conjunction with fulvestrant, an estrogen receptor antagonist [14].